丙型肝炎病毒清除后随时间推移肝细胞癌风险下降
该回顾性队列研究纳入75,965例在2018年1月1日前获得持续病毒学应答(SVR)且至2019年1月1日存活无肝细胞癌(HCC)诊断的丙型肝炎病毒感染退伍军人患者,随访12个月。在肝硬化患者中,与SVR后≥1至2年者相比,SVR后>2至4年和>4至6年者HCC风险逐渐降低,但>6年后风险似乎趋于平稳。无肝硬化患者中HCC风险为0.23-0.27/100人年,SVR后时间与HCC风险无显著关联。
要点
- 肝硬化患者SVR后>4至6年HCC风险较≥1至2年降低(aHR 0.61,95% CI 0.41-0.90)。
- 肝硬化患者SVR后>6年HCC风险趋于平稳(aHR 0.70,95% CI 0.46-1.07)。
- 无肝硬化患者HCC风险为0.23-0.27/100人年,与SVR后时间无显著关联。
核心结论
- 在肝硬化且丙型肝炎治愈的患者中,HCC风险在SVR后至6年期间逐渐下降,但仍远高于需要筛查的阈值。
- SVR后时间可为治愈丙型肝炎患者的HCC监测策略提供信息,并可纳入HCC风险预测模型。
研究设计与样本
- 回顾性队列研究,纳入所有在2018年1月1日前获得SVR且至2019年1月1日存活无HCC诊断的丙型肝炎病毒感染退伍军人事务患者(n=75,965)。
- 以2019年1月1日为零点确定基线特征(包括SVR后累积时间),随访后续12个月内的新发HCC。
- 采用多变量Cox比例风险回归分析SVR后时间与HCC风险的关联,校正年龄、种族/民族、性别、糖尿病、高血压、体重指数、酒精使用、Charlson合并症指数、Fibrosis-4评分、HCV基因型、乙型肝炎病毒共感染和HIV共感染。
主要发现
- 96.0%为男性;平均年龄64.6岁。
- 肝硬化患者(n=19,678,25.9%)中,SVR后>2至4年者HCC发生率为2.11/100人年(aHR 0.80,95% CI 0.63-1.01),SVR后>4至6年者为1.65/100人年(aHR 0.61,95% CI 0.41-0.90),均低于SVR后≥1至2年者的2.71/100人年。
- 肝硬化患者SVR后>6年者HCC发生率为1.68/100人年(aHR 0.70,95% CI 0.46-1.07),风险似乎趋于平稳。
- 无肝硬化患者中HCC风险为0.23-0.27/100人年,SVR后时间与HCC风险无显著关联。
临床怎么用
- 作者认为,SVR后时间可为治愈丙型肝炎患者的HCC监测策略提供信息,并可纳入HCC风险预测模型。
- 肝硬化患者SVR后HCC风险虽随时间下降,但仍远高于需要筛查的阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether the risk of hepatocellular carcinoma (HCC) decreases over time following hepatitis C virus (HCV) eradication. AIM: To determine if patients who have accrued longer time since sustained virologic response (SVR) have a lower risk of HCC than those with less time since SVR METHODS: We conducted a retrospective cohort study of all HCV-infected Veterans Affairs patients who achieved SVR before 1 January 2018 and remained alive without a diagnosis of HCC as of 1 January 2019 (n = 75,965). We ascertained their baseline characteristics as of 1 January 2019 (time zero), including time accrued since SVR and followed them for the subsequent 12 months for incident HCC. We used multivariable Cox proportional hazards regression to determine the association between time since SVR and HCC risk after adjusting for age, race/ethnicity, sex, diabetes, hypertension, body mass index, alcohol use, Charlson Comorbidity Index, Fibrosis-4 score, HCV genotype, hepatitis B virus co-infection and HIV co-infection. RESULTS: 96.0% were male; mean age was 64.6 years. Among those with cirrhosis (n = 19,678, 25.9%), compared to patients who had accrued only ≥1 to 2 years since SVR (HCC incidence 2.71/100 person-years), those who had accrued >2 to 4 years (2.11/100 person-years, aHR 0.80, 95% CI 0.63-1.01) and >4 to 6 years (1.65/100 person-years, aHR 0.61, 95% CI 0.41-0.90) had progressively lower HCC risk. However, HCC risk appeared to plateau for those with >6 years since SVR (1.68/100 person-years, aHR 0.70, 95% CI 0.46-1.07). Among those without cirrhosis, HCC risk was 0.23-0.27/100 person-years without a significant association between time since SVR and HCC risk. CONCLUSIONS: Among patients with cirrhosis and cured HCV infection, HCC risk declined progressively up to 6 years post-SVR-although it remained well above thresholds that warrant screening. This suggests that time since SVR can inform HCC surveillance strategies in patients with cured HCV infection and can be incorporated into HCC risk prediction models.
引用
- Vutien P, Kim NJ, Moon AM, et al. Hepatocellular carcinoma risk decreases as time accrues following hepatitis C virus eradication. Aliment Pharmacol Ther. 2023. PMID: 37955206. doi:10.1111/apt.17802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。